$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

$lsta Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000032001720000036 Filed on May 07, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$0.00	$0.00
YoY Change		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.558M	$2.554M
YoY Change	0.16%	-11.84%
% of Gross Profit
Research & Development	$1.499M	$2.038M
YoY Change	-26.45%	-9.9%
% of Gross Profit
Depreciation & Amortization	$20.00K	$20.00K
YoY Change	0.0%	-77.78%
% of Gross Profit
Operating Expenses	$4.057M	$4.592M
YoY Change	-11.65%	-10.99%
Operating Profit	-$4.057M	-$4.592M
YoY Change	-11.65%	-10.99%
Interest Expense	$70.00K	$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net	$71.00K	$227.0K
YoY Change	-68.72%	29.71%
Pretax Income	-$3.990M	-$4.370M
YoY Change	-8.7%	-12.33%
Income Tax
% Of Pretax Income
Net Earnings	-$3.990M	-$4.367M
YoY Change	-8.63%	-12.38%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.38
Diluted Earnings Per Share	-$0.38	-$435.7K
COMMON SHARES
Basic Shares Outstanding	10.62M shares	9.950M shares
Diluted Shares Outstanding	10.62M shares

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$20.75M	$38.37M
YoY Change	-45.93%	-21.02%
Cash & Equivalents	$20.75M	$14.42M
Short-Term Investments	$0.00	$23.95M
Other Short-Term Assets	$500.0K	$1.300M
YoY Change	-61.54%	-77.59%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$21.21M	$39.65M
YoY Change	-46.51%	-27.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$87.00K	$148.0K
YoY Change	-41.22%	-16.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$847.0K	$1.494M
YoY Change	-43.31%	4.18%
Total Long-Term Assets	$934.0K	$1.642M
YoY Change	-43.12%	-24.93%
TOTAL ASSETS
Total Short-Term Assets	$21.21M	$39.65M
Total Long-Term Assets	$934.0K	$1.642M
Total Assets	$22.14M	$41.29M
YoY Change	-46.38%	-27.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$64.00K	$553.0K
YoY Change	-88.43%	-36.21%
Accrued Expenses	$4.556M	$4.548M
YoY Change	0.18%	-35.01%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.620M	$5.101M
YoY Change	-9.43%	-35.9%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$536.0K	$1.729M
YoY Change	-69.0%	-49.79%
Total Long-Term Liabilities	$536.0K	$1.729M
YoY Change	-69.0%	-49.79%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.620M	$5.101M
Total Long-Term Liabilities	$536.0K	$1.729M
Total Liabilities	$5.156M	$6.830M
YoY Change	-24.51%	-40.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$421.4M	-$402.4M
YoY Change	4.72%	4.04%
Common Stock	$11.00K	$10.00K
YoY Change	10.0%	4.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$708.0K	$708.0K
YoY Change	0.0%	0.05%
Treasury Stock Shares	11.08K shares	11.08K shares
Shareholders Equity	$17.24M	$34.73M
YoY Change
Total Liabilities & Shareholders Equity	$22.14M	$41.29M
YoY Change	-46.38%	-27.2%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$3.990M	-$4.367M
YoY Change	-8.63%	-12.38%
Depreciation, Depletion And Amortization	$20.00K	$20.00K
YoY Change	0.0%	-77.78%
Cash From Operating Activities	-$4.241M	-$5.486M
YoY Change	-22.69%	-12.91%
INVESTING ACTIVITIES
Capital Expenditures	$2.000K	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$11.10M	$8.740M
YoY Change	27.0%	-840.68%
Cash From Investing Activities	$11.10M	$8.741M
YoY Change	27.01%	-835.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$148.0K	$870.0K
YoY Change	-117.01%	-1308.33%
NET CHANGE
Cash From Operating Activities	-$4.241M	-$5.486M
Cash From Investing Activities	$11.10M	$8.741M
Cash From Financing Activities	-$148.0K	$870.0K
Net Change In Cash	$6.713M	$4.125M
YoY Change	62.74%	-154.56%
FREE CASH FLOW
Cash From Operating Activities	-$4.241M	-$5.486M
Capital Expenditures	$2.000K	$0.00
Free Cash Flow	-$4.243M	-$5.486M
YoY Change	-22.66%	-13.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q4	clbs	Preferred Stock Liquidation Preference Share PreferredStockLiquidationPreferenceShare	0.001	shares
CY2019Q4	clbs	Accrued Grant Funding AccruedGrantFunding	1600000	USD
CY2020Q1	clbs	Accrued Grant Funding AccruedGrantFunding	914000	USD
CY2019Q4	clbs	Aggregate Intrinsic Value Warrants Outstanding AggregateIntrinsicValueWarrantsOutstanding	0	USD
CY2020Q1	clbs	Aggregate Intrinsic Value Warrants Outstanding AggregateIntrinsicValueWarrantsOutstanding	0	USD
CY2020Q1	clbs	Aggregate Intrinsic Value Warrantsvested AggregateIntrinsicValueWarrantsvested	0	USD
CY2020Q1	clbs	Preferred Stock Liquidation Preference Share PreferredStockLiquidationPreferenceShare	0.001	shares
CY2019Q4	clbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
CY2020Q1	clbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
CY2018Q1	clbs	Progress Payment On Grant Award Cash Received ProgressPaymentOnGrantAwardCashReceived	300000	USD
CY2020Q1	clbs	Sharesvestedandexpectedtovest Sharesvestedandexpectedtovest	30000	shares
CY2020Q1	clbs	Warrants Canceled WarrantsCanceled	0	shares
CY2020Q1	clbs	Warrants Exercised WarrantsExercised	0	shares
CY2020Q1	clbs	Warrants Expired WarrantsExpired	0	shares
CY2020Q1	clbs	Warrants Granted WarrantsGranted	0	shares
CY2020Q1	clbs	Warrants Vested WarrantsVested	30000	shares
CY2020Q1	clbs	Weighted Average Exercise Price Warrants Canceled WeightedAverageExercisePriceWarrantsCanceled	0.00
CY2020Q1	clbs	Weighted Average Exercise Price Warrants Exercisable WeightedAverageExercisePriceWarrantsExercisable	5.89
CY2020Q1	clbs	Weighted Average Exercise Price Warrants Exercised WeightedAverageExercisePriceWarrantsExercised	0.00
CY2020Q1	clbs	Weighted Average Exercise Price Warrants Expired WeightedAverageExercisePriceWarrantsExpired	0.00
CY2020Q1	clbs	Weighted Average Exercise Price Warrants Granted WeightedAverageExercisePriceWarrantsGranted	0.00
CY2019Q4	clbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	5.89
CY2020Q1	clbs	Aggregate Intrinsic Value Warrantsvestedandexpectedtovest AggregateIntrinsicValueWarrantsvestedandexpectedtovest	0	USD
CY2019Q1	clbs	Aggregate Market Value Of Common Stock Non Affiliates AggregateMarketValueOfCommonStockNonAffiliates	52800000	USD
CY2019Q1	clbs	Amortization Of Accrued Grant Funding Liability To Offset Expense AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense	600000	USD
CY2020Q1	clbs	Amortization Of Accrued Grant Funding Liability To Offset Expense AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense	700000	USD
CY2019Q4	clbs	Common Stock Warrants Shares CommonStockWarrantsShares	30000	shares
CY2020Q1	clbs	Common Stock Warrants Shares CommonStockWarrantsShares	30000	shares
CY2017Q2	clbs	Funding Of Grant Award Cash Received FundingOfGrantAwardCashReceived	5700000	USD
CY2019Q1	clbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-1635000	USD
CY2020Q1	clbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-1443000	USD
CY2019Q4	clbs	Market Capitalization Used In Net Operating Loss Analysis MarketCapitalizationUsedInNetOperatingLossAnalysis	124500000	USD
CY2017Q4	clbs	Milestone Payment On Grant Award Cash Received MilestonePaymentOnGrantAwardCashReceived	1900000	USD
CY2019	clbs	Net Operating Loss Analysis Annual Limitation NetOperatingLossAnalysisAnnualLimitation	3000000	USD
CY2020Q1	clbs	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	5.89
CY2020Q1	clbs	Weighted Average Exercise Price Warrants Vested And Expected To Vest WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest	5.89
CY2020Q1	clbs	Weighted Average Remaining Contractual Term Warrants Vestedand Expectto Vest WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest	P2Y11M12D
CY2019	clbs	Weighted Average Remaining Contractual Termwarrantoutstanding WeightedAverageRemainingContractualTermwarrantoutstanding	P3Y2M9D
CY2020Q1	clbs	Weighted Average Remaining Contractual Termwarrantoutstanding WeightedAverageRemainingContractualTermwarrantoutstanding	P2Y11M12D
CY2020Q1	clbs	Weighted Average Remaining Contractual Termwarrantsvested WeightedAverageRemainingContractualTermwarrantsvested	P2Y11M12D
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000320017
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12840403	shares
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	Caladrius Biosciences, Inc.
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1490000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	64000	USD
CY2019Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-82000	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-19000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4486000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4556000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	438911000	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	439330000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	547000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	567000	USD
CY2019Q4	us-gaap	Assets Assets	27153000	USD
CY2020Q1	us-gaap	Assets Assets	22140000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	25972000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	21206000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	22766000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	17037000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis	17037000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue	17037000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis	0	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	0	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	22768000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	17037000	USD
CY2019Q4	us-gaap	Cash Cash	11643000	USD
CY2020Q1	us-gaap	Cash Cash	17037000	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Grants Receivable GrantsReceivable	12200000	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	2000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4125000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6713000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	4000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14032000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20745000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	22768000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	17037000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10299000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14032000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14424000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20745000	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10528689	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10638771	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10528689	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10638771	shares
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4353000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3992000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	2000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	4000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4351000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-3988000	USD
CY2019Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	17000	USD
CY2020Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	15000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1834000	USD
CY2020Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2286000	USD
CY2020Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	111000	USD
CY2018Q1	us-gaap	Grants Receivable GrantsReceivable	8100000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-91000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-233000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	223000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-354000	USD
CY2019Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	547000	USD
CY2020Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	567000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	986000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	27000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	239000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	414000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	306000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	6600000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	5156000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27153000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22140000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5976000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4620000	USD
CY2019Q4	us-gaap	Marketable Securities MarketableSecurities	11125000	USD
CY2020Q1	us-gaap	Marketable Securities MarketableSecurities	0	USD
CY2019Q4	us-gaap	Minority Interest MinorityInterest	-263000	USD
CY2020Q1	us-gaap	Minority Interest MinorityInterest	-259000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	870000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-148000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8741000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11102000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5486000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4241000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-4367000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-3990000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	227000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	71000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	4592000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	4057000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4592000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4057000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	977000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	875000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	354000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	339000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	906000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	807000	USD
CY2020Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09625
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M20D
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	698000	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1017000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1081000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	847000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	14000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	14000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	14000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	624000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	536000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	227000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	71000	USD
CY2019Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	130000	USD
CY2020Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	148000	USD
CY2019Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	16264000	USD
CY2020Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000	USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	815000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	461000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1000000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2019Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	25005000	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	11104000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-4365000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-3986000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	100000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	87000	USD
CY2019Q2	us-gaap	Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred	200000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2038000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1499000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-417400000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-421390000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2554000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2558000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1000000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	417000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	419000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	20816000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	17243000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	37454000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	34458000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20553000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16984000	USD
CY2019Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	11080	shares
CY2020Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	11080	shares
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	708000	USD
CY2020Q1	us-gaap	Treasury Stock Value TreasuryStockValue	708000	USD
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10027000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10623000	shares
CY2020Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Risks</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

Files In Submission

Name	View Source	Status
0000320017-20-000036-index-headers.html	Edgar Link	pending
0000320017-20-000036-index.html	Edgar Link	pending
0000320017-20-000036.txt	Edgar Link	pending
0000320017-20-000036-xbrl.zip	Edgar Link	pending
clbs-10qx20200331.htm	Edgar Link	pending
clbs-20200331.xml	Edgar Link	completed
clbs-20200331.xsd	Edgar Link	pending
clbs-20200331_cal.xml	Edgar Link	unprocessable
clbs-20200331_def.xml	Edgar Link	unprocessable
clbs-20200331_lab.xml	Edgar Link	unprocessable
clbs-20200331_pre.xml	Edgar Link	unprocessable
clbs-ex311_20200331xq1.htm	Edgar Link	pending
clbs-ex312_20200331xq1.htm	Edgar Link	pending
clbs-ex321_20200331xq1.htm	Edgar Link	pending
clbs-ex322_20200331xq1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

2020 Q1 Form 10-Q Financial Statement

#000032001720000036 Filed on May 07, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA LISATA THERAPEUTICS, INC. Stock $lsta

2020 Q1 Form 10-Q Financial Statement

#000032001720000036 Filed on May 07, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta